This article is more than 5 years old. Information may no longer be current.
Fovista combined with Eylea, Avastin shows no benefit over anti-VEGF monotherapy
Fovista anti-PDGF therapy combined with Eylea or Avastin anti-VEGF therapies failed to show superiority to anti-VEGF monotherapy in its phase 3 clinical trial for the treatment of wet age-related macular degeneration, Ophthotech Corp. announced.
Subjects in the international, multicenter, randomized, double-masked, phase 3 study who received Fovista (pegpleranib) in combination with Eylea (aflibercept, Regeneron) or Avastin (bevacizumab, Genentech) gained a mean of 9.42 letters of vision, compared to 9.04 letters for those receiving either of the monotherapies, according to a company press release.
“We express our sincere appreciation to the patients and clinical investigators and their staffs for their dedication to completing this third phase 3 clinical trial of Fovista in combination with anti-VEGF therapy,” Glenn P. Sblendorio, CEO and president of Ophthotech, said. “This outcome does not affect our strategy as the company moves forward with multiple ongoing or planned clinical programs in orphan retinal diseases coupled with multiple ongoing or planned clinical trials in back of the eye indications.”
The company announced in December 2016 that two phase 3 trials of Fovista combined with Lucentis (ranibizumab) anti-VEGF treatment did not meet their primary endpoints.